$1.25
+0.05 (+4.17%)
Open$1.22
Previous Close$1.20
Day High$1.25
Day Low$1.21
52W High$4.19
52W Low$0.81
Volume—
Avg Volume341.8K
Market Cap14.64M
P/E Ratio—
EPS$-1.55
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+2,508.8% upside
Current
$1.25
$1.25
Target
$32.61
$32.61
$25.28
$32.61 avg
$46.79
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 2.43M | 2.52M | 2.31M |
| Net Income | 150.5K | 215.1K | 194.2K |
| Profit Margin | 6.2% | 8.5% | 8.4% |
| EBITDA | 295.2K | 302.7K | 296.9K |
| Free Cash Flow | 147.2K | 165.8K | 140.8K |
| Rev Growth | +21.7% | -7.9% | -0.3% |
| Debt/Equity | 0.76 | 0.80 | 0.85 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $217.49 | +2.05% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $351.85 | +0.82% | 24.7 | 190.40B |
| GILD | Gilead Sciences Inc | $139.37 | +2.22% | 19.6 | 166.66B |
| VRTX | Vertex Pharmaceuticals Inc | $446.54 | +0.76% | 29.1 | 114.87B |
| REGN | Regeneron Pharmaceuticals | $772.64 | +3.12% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $330.87 | +4.68% | 139.7 | 43.84B |